MaxCyte shared its Q3 2026 earnings and plans to buy Akron Bio to boost its programs.

Nov 10, 2026, 4:42 PM ETDealRead the original at Benzinga

Good for MXCT

MaxCyte agreed to acquire Akron Bio, which could add sales from a supplier already used in 4 approved treatments. Third-quarter sales rose 49%, though the company still expects to use $17 million in cash in 2026.

MXCT · MaxCyte

AI read · Good for MXCT

The AI's read

Akron sells supplies used in cell-therapy production and already supports 4 approved treatments. MaxCyte’s sales grew, and its loss was nearly cut in half. The purchase is not complete yet, and MaxCyte still expects to use $17 million in cash in 2026. It expects cash use to fall below $10 million in 2027 as Akron contributes cash.

Get alerts for MXCT

Follow MaxCyte (MXCT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MXCT

Free on the App Store and Google Play, or on the web.